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ABSTRACT
Introduction: Hyperinsulinaemia and insulin
resistance (IR) are key features of polycystic
ovary syndrome (PCOS) and metabolic syndrome.
The effect of 5 weeks of acupuncture treatment has
been investigated in a completed prospective pilot
trial (Clinicaltrials.gov: NCT01457209), and
acupuncture with electrical stimulation applied to
insulin-resistant rats with dihydrotestosterone-
induced PCOS was shown to improve insulin
sensitivity. Therefore, we now aim to conduct a
prospective pilot study to evaluate whether using
the same acupuncture treatment protocol given
over a longer period of time (6 months) than in the
previous pilot trial will improve insulin sensitivity in
women with PCOS and IR. Our hypothesis is that
acupuncture with combined manual and low-
frequency electrical stimulation of the needles
will improve insulin sensitivity in women with PCOS
and IR.
Methods/analysis: This is a prospective pilot trial.
A total of 112 women with PCOS and IR will be
recruited and categorised according to their body
mass index (BMI) as normal weight (BMI=18.5
−23 kg/m2) or as overweight/obese (BMI>23 kg/m2).
Acupuncture will be applied three times per week
for 6 months at 30 min per treatment. The
primary outcome will be the change in insulin
sensitivity before and after 6 months of acupuncture
treatment, as measured by an oral glucose tolerance
test.
Ethics/dissemination: Ethical approval of this
study has been granted from the ethics committee
of the First Affiliated Hospital of Guangzhou Medical
University (No. 2013039). Written and informed
consent will be obtained from each patient before
any study procedure is performed, according to
good clinical practice. The results of this trial will
be disseminated in a peer-reviewed journal and
presented at international congresses.
Trial registration numbers: NCT02026323 and
ChiCTR-OCH-13003921.
BACKGROUND
Features of polycystic ovary syndrome (PCOS)
include ovulatory dysfunction, clinical and
biochemical signs of hyperandrogenism, and
the presence of polycystic ovaries on pelvic
scanning.1 2 PCOS is the most common endo-
crine and metabolic disorder in reproductive-
age women,2 and is found in 5.6% of Chinese
women aged 19–45 years, as shown in a
recent community-based study.1 The main
metabolic phenotype is hyperinsulinaemia
and insulin resistance (IR), which is observed
in about 50–70% of all women with PCOS.3 4
Importantly, IR can be present in lean and in
obese women with PCOS,5 6 and especially in
those with hyperandrogenism and ovulatory
dysfunction.7 8
PCOS causes signiﬁcant menstrual and
fertility issues, but over the past few decades its
additional metabolic and cardiovascular risks
have become apparent. Women with PCOS
display IR and reduced insulin responsiveness9
and have at least a threefold increased risk
of developing type 2 diabetes mellitus.10 IR in
women with PCOS has been attributed to
postbinding defects in adipocytes and skeletal
muscle insulin signalling.9 11 Furthermore,
compensatory hyperinsulinaemia fuels ovarian
androgen production by stimulating androgen
production and secretion by theca cells, and
by reducing sex hormone-binding globulin
(SHBG) levels, which increases free androgens
and further exacerbates PCOS symptoms.12
Thus, there is a strong association between
hyperinsulinaemia and hyperandrogenaemia.
Overweight/obesity is a common feature
of PCOS.13 A Korean study showed that 61%
of women with PCOS were lean, 10.3%
were overweight and 28.4% were obese.14
Obesity aggravates most of the metabolic
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dysfunctions in women with PCOS. Women with
comorbid PCOS and depression have been found to
have higher body mass index (BMI) and IR compared
with women with PCOS without depression,15 and this
increase in BMI negatively affects quality of life.16
Despite the high prevalence of IR, impaired glucose
tolerance and/or type 2 diabetes mellitus in women
with PCOS, there is no consensus on the best long-term
management of these conditions. Pharmacological treat-
ments, including metformin, are symptom oriented and
usually effective but have unpleasant gastrointestinal side
effects. Therefore, it is important to evaluate other non-
pharmacological treatment strategies because most
women with PCOS require long-term treatment.
Acupuncture, which is one of the main treatment
modalities of traditional Chinese medicine, is increas-
ingly being used in the area of reproductive endocrin-
ology and infertility in many different parts of the
world. Interestingly, increasing the treatment fre-
quency and the number of treatments leads to higher
ovulation frequency,17 indicating the importance of
the correct treatment dose. In a secondary analysis of
the trial by Jedel et al,18 low-frequency electroacupunc-
ture (EA) decreased high plasminogen activator
inhibitor 1 (PAI-1) activity without affecting insulin
sensitivity, as measured by the euglycaemic hyperinsuli-
naemic clamp.19 Clearly, the intensity, frequency and
duration of low-frequency EA treatment in that study
were too low to affect insulin sensitivity. Support for
this assumption comes from our experimental studies
in the dihydrotestosterone (DHT)-induced PCOS rat
model, in which we demonstrated that low-frequency
EA improves whole-body insulin sensitivity in a dose-
dependent manner.20 21
EA induces systemic as well as local effects involving
intracellular insulin signalling pathways in skeletal
muscle and adipose tissue.20 22 23 Furthermore, EA has
been shown to reduce plasma glucose levels by promot-
ing insulin production and to improve insulin sensitiv-
ity by inducing secretion of endogenous β-endorphin
in different rodent models of diabetes mellitus.24 25
The potential role of acupuncture in the treatment of
women with PCOS and IR has not yet been deter-
mined, and this is an important area to investigate
because most women with PCOS require long-term
treatment. There is one completed prospective pilot
trial investigating the effect of 5 weeks of acupuncture
treatment with combined manual and low-frequency
electrical stimulation of the needles (Clinicaltrials.gov:
NCT01457209). Therefore, the aim of this pilot study is
to investigate the clinical effectiveness of acupuncture
on insulin sensitivity in women with PCOS and IR when
acupuncture is given over a longer period of time
(6 months) than in the previous pilot trial using the
same treatment protocol. Our hypothesis is that acu-
puncture with combined manual and low-frequency
electrical stimulation of the needles will improve
insulin sensitivity in women with PCOS and IR.
MATERIALS AND METHODS
Study design
This is a single-centre prospective pilot study, and
participants will be enrolled from the First Afﬁliated
Hospital of Guangzhou Medical University. The trial
has been registered at ClinicalTrial.gov (NCT02026323)
and with the Chinese Clinical Trials Registry
(ChiCTR-OCH-13003921).
Participants
Participants will be recruited if they fulﬁl all of the inclu-
sion criteria and do not meet any of the exclusion
criteria.
Inclusion criteria
1. Age between 18 and 40 years.
2. BMI≥18.5 kg/m2.
3. Presence of PCOS as deﬁned by the Rotterdam cri-
teria and including at least two of the following three
features:
▸ Oligomenorrhoea or amenorrhoea: Oligomenorrhoea
is deﬁned as an intermenstrual interval >35 days or <8
menstrual bleedings in the past year. Amenorrhoea is
deﬁned as complete cessation of menstrual cycles
for 6 months or more when a patient has previously
had regular cycles and for 12 months or more when
the patient has had irregular cycles.
▸ Clinical or biochemical hyperandrogenism:
Biochemical hyperandrogenaemia is deﬁned as a
total serum testosterone concentration above 60 ng/
dL,26 and clinical hyperandrogenism is deﬁned as a
Ferriman-Gallwey (FG) score ≥5, in mainland
China.27
▸ Polycystic ovary morphology: This is deﬁned as ≥12
antral follicles (2–9 mm in diameter) or an ovarian
volume >10 mL on transvaginal scanning.28
4. Presence of IR as deﬁned by the homeostatic
model assessment (HOMA-IR: (fasting insulin
(μU/mL)×fasting glucose (mmol/L))/22.5). A value
≥2.14 will be considered to be indicative of IR.29
5. No desire to bear children and having used barrier
methods of contraception for 1 year.
6. Willingness to sign the consent form.
Exclusion criteria
1. Having other endocrine disorders such as hyperprolac-
tinaemia (deﬁned as two prolactin levels measured at
least 1 week apart of 25 ng/mL or greater or as deter-
mined by local normative values), non-classic congeni-
tal adrenal hyperplasia (17-hydroxyprogesterone
<3 nmol/L), or androgen-secreting tumours.
2. Follicle-stimulating hormone (FSH) levels
>15 mIU/mL. A normal level within the last year is
adequate for entry.
3. Uncorrected thyroid disease deﬁned as thyroid-
stimulating hormone (TSH) <0.2 mIU/mL or
TSH>5.5 mIU/mL. A normal level within the last
year is adequate for entry.
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4. Patients with type I diabetes mellitus or type I and
type II who are receiving antidiabetic medications
such as insulin, thiazolidinediones, acarbose, sulfo-
nylureas, or other medications that are likely to con-
found the effects of the study. Patients currently
receiving metformin for a diagnosis of type I or type
II diabetes or for PCOS are also speciﬁcally
excluded.
5. Suspected Cushing’s syndrome.
6. Use of hormones or other medications in the past
3 months, including Chinese herbal prescriptions,
which might affect the outcome.
7. Pregnancy within the past 6 weeks.
8. Postabortion or post partum within the past 6 weeks.
9. Breast feeding within the past 6 months.
10. Receiving acupuncture treatment related to PCOS
within the past 2 months.
11. Having undergone a bariatric surgery procedure
within the past 12 months or being in a period of
acute weight loss.
12. Having known congenital adrenal hyperplasia.
13. Lack of written consent to participate in the study.
Eligible participants will be recruited and categorised
according to their BMI as normal weight (BMI=18.5–
23 kg/m2) or overweight/obese (BMI≥23 kg/m2).30
Interventions
The acupuncture protocol is based on Western medical
theories, and the study protocol follows the CONSORT31
and STandards for Reporting Interventions in Clinical
Trials of Acupuncture (STRICTA)32 recommendations
with detailed descriptions of the treatment, including
the number of needles used, depth of needle insertion,
how needles will be stimulated (manual or electrical),
frequency of sessions and length of the treatment
period. Acupuncture will be given according to a ﬁxed
protocol by traditional Chinese medicine practitioners
educated in theoretical and practical acupuncture. The
protocol is based on experimental studies elucidating
the effect of acupuncture in rodent models of diabetes
mellitus and PCOS20–22 and in women with PCOS.19 33
Acupuncture protocol
Acupuncture will be given three times per week over
6 months for a total of 80 sessions. Disposable, sterilised
needles for single use made of stainless steel (0.20×30 mm
and 0.20×40/50 mm; Hwoto, Suzhou Medical Appliance
Factory, Suzhou, China) will be inserted to a depth of 15–
35 mm in segmental acupuncture points located in the
abdominal and leg muscles, with innervations correspond-
ing to the ovaries and pancreas that have been shown to
improve insulin sensitivity in rodents. Two sets of acupunc-
ture points will be alternated for every other treatment
session. The two acupuncture protocols follow the
STRICTA recommendations and are presented in table 1.
The rationale for using the traditional nomenclature of
acupuncture points is that they are well described in the lit-
erature, and acupuncturists trained according to medical
acupuncture theories or trained in classic traditional
Chinese medicine theories all know the locations of such
points and how the needles should be inserted. Thus,
using the acupuncture name/number makes it easier for
all practitioners to know where the needles were placed.
All needles will be stimulated manually by rotation until
needle sensation is evoked, which is indicative of activation
of a-delta and c-ﬁbres when the needles are inserted.
Needles placed in the abdominal muscles and leg muscles
will be attached to an electrical stimulator (Export
Abteilung, Schwa-Medico GmbH, Germany) and electric-
ally stimulated at 2 Hz for 30 min during each treatment
session. Needles not connected to the electrical stimulator
will be stimulated manually four times during each 30 min
treatment session (table 1).
Study procedures
This pilot study has two phases. The ﬁrst phase is the
6 months of acupuncture treatment, and the second
phase is 6 months of follow-up (ﬁgure 1). Each speciﬁc
visit and measurement is summarised in table 2.
The women in the study will be screened for IR. Those
with a HOMA-IR ((fasting insulin (μU/mL)×fasting
glucose (mmol/L))/22.5) ≥2.14 will be included and
divided into the normal weight (BMI=18.5–23 kg/m2)
group and the overweight/obese (BMI≥23 kg/m2) group.
After inclusion and baseline measurements, acupuncture
treatment will start and last for 6 months followed by
6 months of follow-up.
Outcome measurements
Primary outcome
The primary outcome will be the changes in HOMA-IR
between baseline and after 6 months of acupuncture
treatment, and between baseline and the 6-month
follow-up. The oral glucose tolerance test (OGTT) with
75 g glucose will be performed in all participants after
an overnight fast. Blood samples will be obtained to
measure plasma glucose and serum insulin at 0, 60 and
120 min during the OGTT.
Secondary outcomes
1. HOMA-B: Islet β-cell function will be evaluated by the
formula (20×fasting insulin (mU/mL)/(fasting plasma
glucose (mmol/L) −3.5))34 and by the C peptide
index (CPI), which is measured as (fasting C peptide
(nmol/L)/fasting plasma glucose (mmol/L)×100).35
2. The insulin response to glucose will be assessed by
calculating the area under the curve during the
OGTT for glucose (AUCglu) and insulin (AUCins)
using the trapezoidal rule.36
3. Menstrual bleeding patterns will be evaluated.
4. Body composition will be determined as weight,
height, waist-to-hip circumference and BMI.
5. Metabolic measures will include glycated haemoglobin,
C peptide, adiponectin, fasting cholesterol, fasting
triglycerides (TG), apolipoprotein A1 (ApoA1), apoli-
poprotein B (ApoB) and blood pressure.
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6. Endocrine measures will include hirsutism as assessed
by FG score, the presence of acne, and serum con-
centrations of testosterone, SHBG, FSH, luteinising
hormone and dehydroepiandrosterone sulfate
(DHEAS).
7. Questionnaires will include the short form-36 (SF36),37
the PCOS questionnaire (PCOSQ),38 generic and
diagnosis-speciﬁc health-related quality of life question-
naires, and the Chinese Quality of Life (ChQOL) ques-
tionnaire.39 Symptoms of anxiety and depression will
be assessed by the Zung Self-Rating Anxiety Scale
(Zung SAS), and the Zung Self-Rating Depression
Scale (Zung SDS).40 In addition, the International
Physical Activity Questionnaire (IPAQ)41 written in
Chinese will be used to measure the frequency and dur-
ation of moderate physical activity every week.
8. Adverse events will be recorded.
Data entry and quality control of data
Case report forms will be developed for data entry, and
quality control of the data will be handled at two differ-
ent levels. The investigators will be required to ensure
the accuracy of the data as the ﬁrst level of control, and
the second level will include data monitoring and valid-
ation that will be carried out on a regular basis through-
out the study.
Sample size calculations and statistical analysis
Our previous study on treating obese women with PCOS
with abdominal acupuncture showed that the HOMA-IR
was signiﬁcantly reduced after treatment (3.9±1.4)
compared with baseline measurements (2.5±1.7).33
A HOMA-IR≥2.14 was considered to be abnormal.29 If
we assume a more moderate 20% reduction in
HOMA-IR, that is, a reduction by 0.78, we will have to
recruit 40 overweight or obese participants and 40
normal-weight participants. With an estimated 40% drop
out rate, we plan to recruit 56 normal weight and 56
overweight/obese women with PCOS.
One sample of the Kolmogorov-Smirnov test will be
used to test the normal distribution of continuous
Figure 1 (IR, insulin resistance; PCOS, polycystic ovary
syndrome).
Table 2 Overview of study visits, including screening, baseline measurements, after-treatment measurements and follow-up
measurements
Screening and
baseline visit
Month Follow-up
6th month1st 2nd 3rd 4th 5th 6th
Body composition (weight, height, waist circumference, hip
circumference)
√ √ √ √ √ √ √ √
Menstrual cycle diary √ √ √ √ √ √ √ √
Fasting blood samples for Apoa1, ApoB, TC, TG, C
peptide, HbA1c
√ √ √
Fasting blood samples for FSH, LH, SHBG, T, E2, P,
DHEAS
√ √ √
Transvaginal ultrasound √ √ √
Questionnaire √ √ √
FG/acne √ √ √ √ √ √ √ √
OGTT √ √ √ √
Months indicate when each specific measurement takes place.
Apoa1, apolipoprotein A1; ApoB, apolipoprotein B; DHEAS, dehydroepiandrosterone sulfate; E2, estradiol; FG, Ferriman-Gallwey score; FSH,
follicle-stimulating hormone; HbA1c, glycated haemoglobin; LH, luteinising hormone; OGTT, oral glucose tolerance test; SHBG, sex
hormone-binding globulin; T, total testosterone; TC, total cholesterol; TG, triglyceride.
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variables. Continuous variables will be shown as means
±SDs if they are normally distributed or as medians with
IQRs if they are not normally distributed. Statistical com-
parisons will be carried out according to the intention
to treat by Student t test, Mann-Whitney U-test, and
Wilcoxon signed-ranks test for continuous variables and
by χ2 tests for categorical variables where appropriate.
All statistical analyses of the data will be performed
using the SPSS program V.21.0 (SPSS Inc, Chicago,
Illinois, USA), and a p value <0.05 will be considered
statistically signiﬁcant.
Safety and ethical considerations
Acupuncture is a safe procedure, and few side effects
have been reported. The major risks of acupuncture are
local skin irritation, discomfort and vasovagal reactions
during the procedure. The women who agree to partici-
pate in the study will sign a consent form.
DISCUSSION
Acupuncture has been used in the treatment of women
with PCOS,17–19 33 but the effect of acupuncture on IR
in women with PCOS is still unknown. This prospective
pilot study has been designed, therefore, to evaluate
whether acupuncture improves insulin sensitivity in
women with PCOS and IR. The research seeks to add
signiﬁcantly to the clinical evidence base and to allow
conclusions to be made on the role of acupuncture in
the treatment of PCOS.
A limitation of the present study is that it is a single-
centre study without comparison groups, and it can be
argued that it lacks scientiﬁc rigour because of this. To
increase the validity of the study, we will have experts
controlling the quality of study procedure through
regular site visits. The experts will monitor the recruit-
ment of study participants, the measurement and treat-
ment procedures, and the data analysis. We plan to
conduct a randomised controlled trial at a later date
using standard care as a control.
This pilot study was conceived and designed in 2013, and
the ﬁrst participant was recruited on 18 February 2014. As
of 18 December 2014, out of 368 women approached, 176
did not fulﬁl selection criteria, 85 declined participation
and 107 consented to participate in the study. In total, 99
women were screened and 83 were recruited.
Author affiliations
1Research Institute of Integrated Traditional Chinese Medicine and Western
Medicine, Guangzhou Medical University, Guangzhou, China
2Department of Traditional Chinese Medicine, The Fourth Affiliated Hospital of
Guangzhou Medical University, Guangzhou, China
3Department of Physiology and Pharmacology, Karolinska Institutet,
Stockholm, Sweden
4Department of Obstetrics and Gynaecology, The University of Hong Kong,
Hong Kong Special Administrative Region, Hong Kong, Hong Kong
5Department of Traditional Chinese Medicine, The First Affiliated Hospital of
Guangzhou Medical University, Guangzhou, China
6Department of Gynecology, First Affiliated Hospital National Key Discipline,
Specialty and Trial Base Heilongjiang University of Chinese Medicine, China
Contributors YZ, ES-V and EHYN contributed equally to this work. ES-V,
EHYN and HM conceived and designed the study. YZ, EHYN and ES-V drafted
and critically revised the manuscript for important intellectual content. HM
sought funding and ethical approval. All the authors contributed to the further
writing of the manuscript and approved the final manuscript.
Funding This work was supported in part by the National Foundation of
Natural Science of China (grant number 81273786), the Science and
Technology Planning Project of Guangdong Province in China (grant number
2011B031700042) and funded by the national clinical trial base ‘Optimization
study of traditional Chinese medicine therapy for women with polycystic ovary
syndrome’ (grant number JDZX2012043).
Competing interests None declared.
Patient consent Obtained.
Ethics approval This study was approved by the ethics committee of the First
Affiliated Hospital of Guangzhou Medical University (No. 2013039).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional date are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary
syndrome in women in China: a large community-based study.
Hum Reprod 2013;28:2562–9.
2. Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome.
Lancet 2007;370:685–97.
3. Legro RS, Castracane VD, Kauffman RP. Detecting insulin
resistance in polycystic ovary syndrome: purposes and pitfalls.
Obstet Gynecol Surv 2004;59:141–54.
4. Yin Y, Hong-mei X, Guang-xiu L. Analysis of insulin resistance and
metabolism characteristic of the Hans PCOS women. China J Mod
Med 2007;17:1625–30.
5. Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in
nonobese patients with polycystic ovarian disease. J Clin Endocrinol
Metab 1983;57:356–9.
6. Stepto NK, Cassar S, Joham AE, et al. Women with polycystic
ovary syndrome have intrinsic insulin resistance on euglycaemic-
hyperinsulaemic clamp. Hum Reprod 2013;28:777–84.
7. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s
health aspects of polycystic ovary syndrome (PCOS): the
Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus
Workshop Group. Fertil Steril 2012;97:28–38.e25.
8. Moran L, Teede H. Metabolic features of the reproductive
phenotypes of polycystic ovary syndrome. Hum Reprod Update
2009;15:477–88.
9. Ciaraldi TP, Aroda V, Mudaliar S, et al. Polycystic ovary syndrome is
associated with tissue-specific differences in insulin resistance.
J Clin Endocrinol Metab 2009;94:157–63.
10. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and
predictors of the metabolic syndrome in women with polycystic ovary
syndrome. J Clin Endocrinol Metab 2006;91:48–53.
11. Dunaif A, Wu X, Lee A, et al. Defects in insulin receptor signaling in
vivo in the polycystic ovary syndrome (PCOS). Am J Physiol
Endocrinol Metab 2001;281:E392–99.
12. Corbould A. Effects of androgens on insulin action in women: is
androgen excess a component of female metabolic syndrome?
Diabetes Metab Res Rev 2008;24:520–32.
13. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, et al.
Prevalence and characteristics of the polycystic ovary syndrome in
overweight and obese women. Arch Intern Med 2006;166:2081–6.
14. Lee H, Oh JY, Sung YA, et al. The prevalence and risk factors for
glucose intolerance in young Korean women with polycystic ovary
syndrome. Endocrine 2009;36:326–32.
15. Hollinrake E, Abreu A, Maifeld M, et al. Increased risk of depressive
disorders in women with polycystic ovary syndrome. Fertil Steril
2007;87:1369–76.
6 Zheng Y, et al. BMJ Open 2015;5:e007757. doi:10.1136/bmjopen-2015-007757
Open Access
 o
n
 27 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-007757 on 3 May 2015. Downloaded from 
16. Jones GL, Balen AH, Ledger WL. Health-related quality of life in
PCOS and related infertility: how can we assess this? Hum Fertil
(Camb) 2008;11:173–85.
17. Johansson J, Redman L, Veldhuis PP, et al. Acupuncture for
ovulation induction in polycystic ovary syndrome: a randomized
controlled trial. Am J Physiol Endocrinol Metab 2013;304:
E934–43.
18. Jedel E, Labrie F, Oden A, et al. Impact of electro-acupuncture and
physical exercise on hyperandrogenism and oligo/amenorrhea in
women with polycystic ovary syndrome: a randomized controlled
trial. Am J Physiol Endocrinol Metab 2011;300:E37–45.
19. Stener-Victorin E, Baghaei F, Holm G, et al. Effects of acupuncture
and exercise on insulin sensitivity, adipose tissue characteristics,
and markers of coagulation and fibrinolysis in women with polycystic
ovary syndrome: secondary analyses of a randomized controlled
trial. Fertil Steril 2012;97:501–8.
20. Johansson J, Yi F, Shao R, et al. intense acupuncture normalizes
insulin sensitivity, increases muscle GLUT4 content, and improves
lipid profile in a rat model of polycystic ovary syndrome. Am J
Physiol Endocrinol Metab 2010;299:E551–9.
21. Manneras L, Jonsdottir IH, Holmang A, et al. Low-frequency
electro-acupuncture and physical exercise improve metabolic
disturbances and modulate gene expression in adipose tissue in rats
with dihydrotestosterone-induced polycystic ovary syndrome.
Endocrinology 2008;149:3559–68.
22. Liang F, Chen R, Nakagawa A, et al. Low-frequency
electroacupuncture improves insulin sensitivity in obese diabetic
mice through activation of SIRT1/PGC-1α in skeletal muscle.
Evid Based Complement Alternat Med 2011;2011:735297.
23. Johansson J, Manneras-Holm L, Shao R, et al. Electrical vs manual
acupuncture stimulation in a rat model of polycystic ovary syndrome:
different effects on muscle and fat tissue insulin signaling.
PLoS ONE 2013;8:e54357.
24. Chang SL, Lin JG, Chi TC, et al. An insulin-dependent
hypoglycaemia induced by electroacupuncture at the Zhongwan
(CV12) acupoint in diabetic rats. Diabetologia 1999;42:250–5.
25. Chang S-L, Lin K-J, Lin R-T, et al. Enhanced insulin sensitivity using
electroacupuncture on bilateral Zusanli acupoints (ST 36) in rats.
Life Sci 2006;79:967–71.
26. Shi Y, Guo M, Yan J, et al. Analysis of clinical characteristics in
large-scale Chinese women with polycystic ovary syndrome. Neuro
Endocrinol Lett 2007;28:807–10.
27. Zhao X, Ni R, Li L, et al. Defining hirsutism in Chinese women:
a cross-sectional study. Fertil Steril 2011;96:792–6.
28. Balen AH, Laven JSE, Tan S-L, et al. Ultrasound assessment of the
polycystic ovary: international consensus definitions. Hum Reprod
Update 2003;9:505–14.
29. Chen X, Yang D, Li L, et al. Abnormal glucose tolerance in Chinese
women with polycystic ovary syndrome. Hum Reprod
2006;21:2027–32.
30. Misra A, Chowbey P, Makkar BM, et al. Consensus statement for
diagnosis of obesity, abdominal obesity and the metabolic syndrome
for Asian Indians and recommendations for physical activity, medical
and surgical management. J Assoc Physicians India 2009;57:163–70.
31. Moher D, Schulz KF, Altman D. The CONSORT Statement: revised
recommendations for improving the quality of reports of parallel-
group randomized trials 2001. Explore (NY) 2005;1:40–5.
32. MacPherson H, Altman DG, Hammerschlag R, et al. Revised
STandards for Reporting Interventions in Clinical Trials of
Acupuncture (STRICTA): extending the CONSORT statement.
PLoS Med 2010;7:e1000261.
33. Lai MH, Ma HX, Yao H, et al. [Effect of abdominal acupuncture
therapy on the endocrine and metabolism in obesity-type
polycystic ovarian syndrome patients]. Zhen Ci Yan Jiu
2010;35:298–302.
34. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model
assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia
1985;28:412–19.
35. Iwata M, Maeda S, Kamura Y, et al. Genetic risk score constructed
using 14 susceptibility alleles for type 2 diabetes is associated with
the early onset of diabetes and may predict the future requirement of
insulin injections among Japanese individuals. Diabetes Care
2012;35:1763–70.
36. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the
relationship between insulin sensitivity and beta-cell function in
human subjects. Evidence for a hyperbolic function. Diabetes
1993;42:1663–72.
37. McHorney CA, Ware JE Jr, Lu JF, et al. The MOS 36-item
Short-Form Health Survey (SF-36): III. Tests of data quality, scaling
assumptions, and reliability across diverse patient groups. Med Care
1994;32:40–66.
38. Cronin L, Guyatt G, Griffith L, et al. Development of a health-
related quality-of-life questionnaire (PCOSQ) for women with polycystic
ovary syndrome (PCOS). J Clin Endocrinol Metab 1998;83:1976–87.
39. Leung KF, Liu FB, Zhao L, et al. Development and validation of the
Chinese Quality of Life Instrument. Health Qual Life Outcomes
2005;3:26.
40. Marone J, Lubin B. Relationship between set 2 of the Depression
adjective check lists (DACL) and Zung self-rating depression scale
(SDS). Psychol Rep 1968;22:333–4.
41. Craig CL, Marshall AL, Sjostrom M, et al. International physical
activity questionnaire: 12-country reliability and validity. Med Sci
Sports Exerc 2003;35:1381–95.
Zheng Y, et al. BMJ Open 2015;5:e007757. doi:10.1136/bmjopen-2015-007757 7
Open Access
 o
n
 27 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-007757 on 3 May 2015. Downloaded from 
